Figure 1From: A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancerImmunohistochemical staining for HER-2 protein overexpression using the HercepTest showed weak membrane staining in 30% of the primary tumor, corresponding to a 1+ score.Back to article page